Analysis of primary patency rate and influencing factors of ultrasound-guided percutaneous transluminal angioplasty for the treatment of arteriovenous fistula dysfunction.

The use of prosthetic grafts such as polytetrafluorethylene (PTFE) or Dacron to bypass occluded arteries in the lower leg is an accepted practice in the absence of suitable autologous vein. The aim is limb salvage or functional improvement in critical limb ischaemia, but patency rates for below knee prosthetic bypasses are low. Creating a vein cuff at the distal anastomosis is thought to improve outcomes. Other techniques including the use of pre-cuffed synthetic grafts, spliced segments of vein and the creation of an arterio-venous fistula (AVF) are also used to improve patency. To compare the beneficial effects of using vein cuffed prosthetic grafts for below knee bypass in critical limb ischaemia with other types of reconstruction. The Cochrane Peripheral Vascular Diseases Group Trials Search Co-ordinator searched the Specialised Register (last searched May 2012) and CENTRAL (2012, Issue 5) for publications comparing prosthetic infragenicular bypass using vein cuffs with other bypass techniques. Randomised controlled trials comparing interposition vein cuff prosthetic graft with autologous vein graft and non-cuffed prosthetic graft for infragenicular bypass in patients with critical limb ischaemia were included. Trials comparing vein cuff prosthetic grafts with or without AVF and vein cuff prosthetic grafts with pre-cuffed prosthetic grafts were also included. The trials were selected and assessed independently by two review authors. Six trials with a combined total of 885 patients were included in this review. Only studies using prosthetic PTFE grafts were identified.Two trials compared PTFE graft with or without a vein cuff. In one underpowered trial for below knee bypass the cumulative primary patency rate was statistically significantly higher in the vein cuff group (80.3% versus 65.3% at 12 months and 51.8% versus 29.1% at 24 months, P = 0.03). There was no statistically significant difference in secondary patency (82.9% versus 72.5% and 58.6% versus 34.9%, P = 0.14) and limb salvage rates (86.3% versus 71.8% and 82.6% versus 62.2%, P = 0.08) at 12 and 24 months respectively. The other trial showed no statistically significant difference between the groups at three years in the below knee femoro-popliteal bypasses (primary patency rate 26% (95% confidence interval (CI) 18 to 38) and 43% (95% CI 33 to 58), secondary patency rate 32% (95% CI 23 to 44) and 42% (95% CI 31 to 56) and limb salvage rate 64% (95% CI 54 to 75) and 61% (95% CI 50 to 74) in the collar and no collar groups respectively). In the femoro-distal bypass group, the differences in primary patency, secondary patency and limb salvage rates were also not statistically significant at three years (primary patency rate 20% (95% CI 11 to 38) and 17% (95% CI 9 to 33), secondary patency rate 22% (95% CI 12 to 39) and 20% (95% CI 11 to 35) and limb salvage rate 59% (95% CI 46 to 76) and 44% (95% CI 32 to 61) in the collar and no collar groups respectively).One trial compared pre-cuffed PTFE grafts with vein cuffed grafts. There was no statistically significant difference in primary patency rate (62% pre-cuffed PTFE versus 52% vein cuff PTFE and 49% versus 44%, P = 0.53), secondary patency rate (66% pre-cuffed PTFE versus 53% vein cuff PTFE and 55% versus 50%, P = 0.30) or limb salvage rate (75% pre-cuffed PTFE versus 72% vein cuff PTFE and 62% versus 65%, P = 0.88) at 12 and 24 months respectively.One trial compared spliced vein grafts with vein cuffed PTFE grafts. At 24 months, the secondary patency rate was statistically significantly higher in the spliced vein group (86% in the spliced vein and 52% in the vein cuff group, P < 0.05). There was no statistical significant difference in primary patency rate (44% versus 50%, P > 0.05) and limb salvage rate (94% versus 85%, P > 0.05).Two trials compared vein cuff PTFE grafts with and without AVF. There was no statistical significant difference at 24 months in primary patency rate (29% versus 36%, P = 0.77; 32% versus 28%, P = 0.2), secondary patency rate (40% versus 40%, P = 0.89; 28% versus 24%, P = 0.2) and limb salvage rate (65% versus 70%, P = 0.97; 62% versus 71%, P = 0.3). There is evidence that a vein cuff at the distal anastomosis site improves primary graft patency rates for below knee PTFE graft, but this does not reduce the risk of limb loss. Pre-cuffed PTFE grafts have comparable patency and limb salvage rates to vein cuff PTFE grafts. The use of spliced veins improved secondary patency but this did not translate into improved limb salvage. The use of an AVF alone showed no added benefits. Evidence for a beneficial effect of vein cuffed PTFE grafts is weak and based on underpowered trials. A large study with a specific focus on below knee vein cuff prosthetic grafts, including PTFE, is required.

Objective This study analyzed the long-term arteriovenous fistula (AVF) patency rate and its determinants in patients undergoing maintenance hemodialysis. Methods General data and laboratory examinations of hemodialysis patients were collected retrospectively. The primary patency time, primary functional patency time, cumulative patency time, cumulative functional patency time, and temporary central venous catheterization (CVC) time were counted. Cox regression was used to analyze the relationships between different factors and AVF survival time. Kaplan-Meier survival analysis was used to analyze the primary patency, primary functional patency, cumulative patency, and cumulative functional patency rates between different groups. Results A total of 174 patients were included (mean age 58.38 ± 15.35 years), 57 women (32.76%) and 68 diabetics (39.08%). Univariate and multivariate Cox regression showed a correlation between UCR and AVF primary patency time, primary functional patency time, cumulative patency time, and cumulative functional patency time (HR 1.127, 1.116, 1.127, 1.115, 1.088, 1.075, 1.087, 1.013; 95%CI 1.055–1.204, 1.043–1.194, 1.055–1.204, 1.042–1.194, 1.022–1.158, 1.006–1.149, 1.021–1.157, 1.004–1.147; p < 0.001, 0.001, <0.001, 0.002, 0.008, 0.033, 0.009, 0.039, respectively). Duration of temporary CVC was also correlated (HR 1.013, 1.013, 1.013, 1.014, 1.008, 1.008, 1.008, 1.008; 95%CI 1.007–1.018, 1.008–1.019, 1.008–1.019, 1.009–1.020, 1.004–1.012, 1.004–1.012, 1.004–1.012, 1.004–1.012; p < 0.001, <0.001, <0.001, <0.001, <0.001, <0.001, <0.001, <0.001, respectively). Female sex was correlated with the primary patency time and the primary functional patency time (HR 1.755, 1.765, 1.767; 95%CI 1.028–2.997, 1.034–3.014, 1.021–3.057; p = 0.039, 0.037, 0.042, respectively), but not with the cumulative patency time and the cumulative functional patency time, the primary patency rate and primary functional patency rate of AVF were higher in male than in female patients (χ2 = 4.439, 4.531; p = 0.035, 0.033, respectively). The primary patency rate, primary functional patency rate, cumulative patency rate, and cumulative functional patency rate of AVF with UCR > 10.11 group are lower than those with UCR ≤ 10.11 (χ2 = 10.745, 10.712, 4.605, 4.472; p = 0.001, 0.001, 0.032, 0.034, respectively). The group of DTCP ≤ 42 days is better than DTCP > 42 days (χ2 = 6.014, 6.055, 8.572, 8.461; p = 0.014, 0.014, 0.003, 0.004, respectively). Conclusion Women with high UCR values at the beginning of dialysis and a long duration of temporary CVC have a poor long-term survival rate of AVF. Therefore, UCR can be used as an indicator to predict the long-term survival rate of AVF. Simultaneously, clinicians should remove the temporary catheter as early as possible if conditions permit it.

Background: Failure of arteriovenous access for hemodialysis is a challenging problem. Maintaining the patency of this access is one of the most important corner stones in the care of patients with chronic renal failure. Recently, percutaneous transluminal balloon angioplasty (PTA) is considered the first line of treatment for dealing with this issue. Aim: The purpose of this retrospective observational study was to evaluate the primary and secondary patency rates after initial endovascular intervention to restore and preserve the patency of failing autogenous arteriovenous fistulae and to identify the potential factors that affect the durability of the procedure. Methods:The results of 56 patients with failing autogenous arteriovenous fistulae were retrospectively analyzed after being treated with percutaneous transluminal balloon angioplasty from November 2014 to December 2018. Technical & clinical success rates were reported. The variables, including patients’ demographics, co-morbidities, medications, fistula age, fistula type, site, number of lesions and degree of stenosis were analyzed and correlated with primary and secondary patency rates. Results: The mean age of the fistulae included in the study since their creation was 17.4 ± 9.6 months, most of which were radiocephalic fistulas (64.3%). The most common cause of autogenous access dysfunction was 90-99% stenosis while the most common site of stenosis was juxta-anastomotic. Technical and clinical success rates of the study population were 92.9% and 89.3%, respectively. The mean primary and secondary patency were 12.3 and 19.9 months, respectively. Primary patency rates at 6,12,18 and 24 months were 79%, 64%, 57% and 44% respectively. Secondary patency rates at 6,12,18 and 24 months were 85%, 76%, 68% and 52% respectively. Patient age ≥ 60 years old was associated with reduced post-PTA primary patency (P < 0.001) and secondary patency (P = 0.018). Dyslipidemia showed marked decrease in both primary and secondary patency rates (P < 0.001). Insulin intake (P < 0.001) was a predictor of primary patency decrease while use of antiplatlets was to a less extent predictor of secondary patency loss (P = 0.004). Radiocephalic fistulae had short primary patency (P = 0.016), while stenotic lesions > 90% showed a significant decrease (P < 0.001) in primary patency more obvious than with secondary patency (P = 0.006). Lesions at arteriovenous anastomosis were significantly associated with decrease in primary patency (P < 0.001). Statins were the only medications associated with longer primary patency (P < 0.001). Age of fistula and number of lesions were independent factors. Conclusion: Endovascular treatment is both safe and effective in managing failing autogenous arteriovenous fistulas. Although its technical and success rates are high, primary and secondary patency rates are still questionable. Dyslipidemia, insulin, statin and antiplatelet intake together with age of patient, degree and site of stenosis are potential risk factors that affect these rates.

The aim was to report the mid-term outcomes of Jetstream™ rotational atherectomy device in complex femoropopliteal lesions. Between November 2016 and April 2018, 55 patients who were treated with rotational atherectomy and adjunctive balloon angioplasty due to complex femoropopliteal lesions were retrospectively scanned. Fifty-five patients who underwent endovascular treatment with rotational atherectomy for chronic total occlusive femoropopliteal lesions were included in the study. Technical success rate was 100%. The mean age was 63 (±10.5) years. The cohort included 25 (45.4%) diabetics and 45 (81.8%) current smokers. The mean length of the lesions was 20.8 ± 11.2 cm. Chronic total occlusive lesions were detected in 35 (63.6%) patients, and mixed-type steno-occlusive lesions were detected in 20 patients (36.4%). Thirty-three (60%) lesions were moderate or severely calcified. Adjunctive balloon angioplasty was performed with plain old balloon angioplasty (POBA) on 31 (56.4%) patients and with drug-coated balloon angioplasty on 24 (43.6%) patients. After adjunctive balloon angioplasty, flow limiting dissection was observed in 20 (36.3%) patients, and 17 (30.9%) patients needed stent implantation. The Kaplan-Meier analysis method estimated that the overall primary patency rates at 12 and 24 months were 81.8% and 70.9%, respectively. Overall, secondary patency rates at 12 and 24 months were 94.5% and 80%. No statistically significant differences of 24-month primary patency and secondary patency rates were found between patients treated with drug-coated balloon angioplasty and POBA as an adjunctive therapy, even though primary patency (83.3% vs. 61.3%, p = .06) and secondary patency (91.7% vs. 71%, p = .56) rates of drug-coated balloon angioplasty were slightly higher than POBA. Patients with claudication had better primary patency (90.5% vs. 58.8%, p = .001) and secondary patency (100% vs. 67.6%, p = .004) rates than patients with critical limb ischemia at 24 months. Significant differences between patients who did and did not stop smoking were found in 24-month primary patency (57% vs. 88%, p = .007) and secondary patency (67% vs. 96%, p = .007). Six patients underwent unplanned amputation. There were eight (14.5%) mortalities during follow-up. Rotational atherectomy with adjunctive balloon angioplasty has satisfactory technical success rates and mid-term outcomes. As an adjunctive method, there was no difference between drug-coated balloon angioplasty s and POBAs. Smoking cessation is always the first-step treatment to improve mid-term patency results. Patients with critical limb ischemia have worse patency results compared to the patients with claudication.

Background: Neointimal hyperplasia (NIH) is believed to be the main reason for arteriovenous fistula (AVF) dysfunction, but other mechanisms are also recognized to be involved in the pathophysiological process. This study investigated whether different morphological types of AVF lesions are associated with the patency rate after percutaneous transluminal angioplasty (PTA). Methods: This retrospective study included 120 patients who underwent PTA for autogenous AVF dysfunction. All the cases were evaluated under Doppler ultrasound (DU) before intervention and divided into 3 types: Type I (NIH type), Type II (non-NIH type), and Type III (mixed type). Prognostic and clinical data were analyzed by Kaplan-Meier analysis and the Cox proportional hazards model. Results: There was no statistical difference in baseline variables among groups, except for lumen diameter. The primary patency rates in Type I, Type II, and Type III groups were 78.4, 93.2, and 83.2% at 6 months and 59.5, 84.7, and 75.5% at 1 year, respectively. The secondary patency rates in Type I, Type II, and Type III groups were 94.4, 97.1, and 100% at 6 months and 90.5, 97.1, and 94.7% at 1 year, respectively. The Kaplan-Meier curve showed that the primary and secondary patency rates of Type I group were lower than those of Type II group. Multivariable Cox regression analysis demonstrated that postoperative primary patency was correlated with end-to-end anastomosis (hazard ratio [HR] = 2.997, p = 0.008, 95% confidence interval [CI]: 1.328–6.764) and Type I lesion (HR = 5.395, p = 0.004, 95% CI: 1.730–16.824). Conclusions: NIH-dominant lesions of AVF evaluated by DU preoperatively were a risk factor for poor primary and secondary patency rate after PTA in hemodialysis patients.

To compare the safety and efficacy of X-ray-guided and ultrasound-guided percutaneous transluminal angioplasty in treating arteriovenous fistula dysfunction. Data for 219 patients with arteriovenous fistula dysfunction between January 2016 and December 2018 were retrospectively analyzed. The primary endpoints were technical success, clinical success, and primary patency rates. The secondary endpoints were complications and secondary patency rates. Procedure outcomes and both endpoints were evaluated by propensity score analysis. After the propensity score matching, 73 matched pairs of cases were created with 34 pairs of autogenous arteriovenous fistula cases and 39 pairs of prosthetic arteriovenous graft cases. There was no significant difference between the X-ray-guided and ultrasound-guided group, respectively, regarding the technical success rate (84.9% vs 87.7%, p = 0.630), clinical success rate (98.6% vs 97.3%, p = 0.999), and complications (10.9% vs 5.5%, p = 0.228). Although the 6- and 12-month secondary patency rates for the dialysis access between the two groups had significant difference (p < 0.05), there was no significant difference in primary and secondary patency curves between the two groups (p > 0.05). The overall efficacy of ultrasound-guided versus X-ray-guided percutaneous transluminal angioplasty in treating arteriovenous fistula dysfunction might be comparable.

Endovascular treatment for immature autogenous arteriovenous fistula

Durability and cumulative functional patency of transposed and nontransposed arteriovenous fistulas.

The aim of this study was to evaluate the midterm performance of brachial vein arteriovenous fistulas (AVFs) and to compare this performance with arteriovenous grafts (AVGs) and basilic vein transposition AVFs. A retrospective analysis was performed. Between December 2002 and October 2006, 149 AV access procedures consisting of brachial vein transposition AVFs (11 one-stage and 2 two-stage procedures), basilic vein transposition AVFs (n=42), and AVGs (n=94) were performed in 141 patients. 73% of one-stage brachial vein AVF patients experienced at least one complication during follow-up vs. 52% of the basilic vein transposition AVF group and 55% of the AVG group. The primary patency rates at 12 months for one-stage brachial vein AVFs, basilic vein AVFs, and AVGs were 24, 45 and 50%, respectively. The assisted primary patency rates were 45, 74 and 63%, and the secondary patency rates were 45, 74 and 78%, respectively. A significant difference in the overall secondary patency rates between one-stage brachial vein AVF and AVGs (p=0.015) was detected. Significance was approached between one-stage brachial vein AVFs and basilic vein AVFs overall assisted primary patency (p=0.055) and secondary patency (p=0.055) rates. The brachial vein transposition, when done as a one-stage procedure, is associated with inferior patency rates when compared to the basilic vein transposition AVF and AVG. Therefore, in the setting of inadequate cephalic and basilic vein, a prosthetic graft is superior to a brachial vein transposition. A two-stage procedure, as suggested by others, may improve the results of this technique.

Predicting loss of patency after forearm loop arteriovenous graft

Arteriovenous fistula outcomes in the elderly

The types of fistulae used and their complication rates are important for the hemodialysis patients. We aimed to compare retrospectively the primary and secondary patency rates and complications of upper extremity arteriovenous fistulae. Between 1984 and 2005, a total of 1,233 upper extremity arteriovenous fistulae were created in 920 patients. The mean age was 42 +/- 21 years. The fistulae were divided into the 3 groups; 588 radiocephalic, 205 brachiocephalic, and 127 were created by polytetrafluoroethylene graft. The fistulae types were evaluated with regard to their primary-secondary patency rates and complications. There was a significant difference with regard to development of thrombosis in radiocephalic group compared to other two groups, respectively, p = 0.0122, p = 0.0091. In brachiocephalic fistulae group, edema and steal phenomenon were statistically significant (p < 0.0001). The aneurysm formation was statistically significant in polytetrafluoroethylene fistulae graft group (p < 0.0001). During 6 months, 2 and 5 years period, while primary patency rate was higher in three fistulae types, in radiocephalic fistulae both primary and secondary fistulae patency rates were lower (p < 0.05). To create successful arteriovenous fistulae with long-term patency, appropriate veins of patients should be carefully preserved; thus initially a distal site should be preferred, and in case of failure the next fistulae should be created proximally. In case of failure of forearm fistulae, primary fistulae with autogenous veins should be tried at the upper arm first, and if this also fails, fistulae formation with synthetic grafts should be considered.

Objective: To summarize the clinical effect of ultrasound-guided percutaneous transluminal angioplasty (PTA) in the treatment of arteriovenous fistula (AVF) immaturation under day surgery mode. Methods: The clinical data was retrospective analyzed of patients with AVF immaturation who were treated by ultrasound-guided PTA under day surgery mode from November 2016 to June 2019 in Renji Hospital. The basic information, lesion location, puncture approach, number and diameter of balloon used were counted. The primary and secondary patency rates were calculated at 6 and 12 months after operation. Results: In all of the 21 patients, 11 patients were male and 10 patients were female. The mean age was (52.6±12.9) years old. There were 20 of the 21 patients who were treated successfully. One patient had AVF reconstruction with vascular rupture, and the complication rate was 4.8% (1/21). The length of hospitalization was (1.05±0.71) days, and the cost was (11 487.7±4 401.4) yuan. The follow-up time was (19.7±8.3) months. The 6-month and 12-month primary patency rate were 70% and 55%, and the 6-month and 12-month secondary patency rate were both 90%. Conclusion: Ultrasound-guided PTA in the treatment of AVF immaturation under day surgery mode is safe and effective, which has a high technical success rate and good patency rate for AVF maturation.

A comparison of arteriovenous grafts and fistulas in lower extremity hemodialysis procedures.

An arteriovenous fistula is the first choice of vascular access in dialysis patients. However, the correlations between patient factors and the arteriovenous fistula patency rate remain unclear. Therefore, we examined the effect of dialysis patient factors on arteriovenous fistula patency rate. This study included 101 patients who received maintenance dialysis and used arteriovenous fistula for vascular access at Atami Hospital, International University of Health and Welfare in July 2018. A retrospective review was performed from the time of arteriovenous fistula creation to July 2018, and the primary and secondary arteriovenous fistula patency rates were investigated. The patency rate was calculated using the Kaplan-Meier method, and risk factor analysis was performed using Cox proportional hazards regression analysis. The primary patency rate of arteriovenous fistula was 71.2% at one year and 43.0% at five years, and the secondary patency rate was 92.7% at one year and 79.8% at five years. In the multivariate analysis, high low-density lipoprotein cholesterol (LDL-C) level and a history of diabetes were considered significant risk factors (HR 1.023, p value <0.01 and HR 2.550, p value <0.01, respectively). A log rank test was conducted on the groups of patients with LDL <90 mg/dl and LDL ≥90 mg/dl, and the <90 mg/dl group resulted in a good primary patency rate (p value 0.0327). High LDL-C level was considered the independent risk factors of arteriovenous fistula primary patency rate.